Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China

SUZHOU,China,Oct.21,2021 --Kintor Pharmaceutical Limited ("Kintor Pharma",HKEX: 9939),a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics,announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) for the treatment of advanced solid tumours was approved by the National Medical Products Administration (NMPA) of Chinaon 21October 2021.

GT90008 is a PD-L1/TGF-β dualtargeting antibody which has a high activity in inhibiting both PD-L1 and TGF-βR2.GT90008 has the potential to be a best-in-class drug globally. Kintor Pharma obtained an exclusive license in Greater China for GT90008 from US-based company Gensun in August 2020.

Dr. Youzhi Tong,founder,Chairman and CEO of Kintor Pharma,commented,"We are delighted to obtain the approval from NMPA to conduct the clinical trial of PD-L1/TGF-β dual-targeting antibody. GT90008 is the secondnovelantibodydrug that has entered the clinical stage. The rapid progress from in-license to IND approval has demonstrated our team's great execution capability. Though there has been headwind on dual-targets antibody of this category,we are confident with our antibody and actively exploring the combination therapies with our GT90001(ALK-1) antibody on advanced tumours. We wish the combo design of GT90008 and GT90001 would benefit patients with advanced tumours."

About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs,including COVID-19,prostate,breast and liver cancer,alopecia and acne. For more information,visit www.kintor.com.cn.

View original content:https://www.prnewswire.com/news-releases/kintor-pharma-announces-pd-l1tgf--dual-targeting-antibody-gt90008-approved-for-advanced-solid-tumour-clinical-trial-in-china-301405880.html